Sutrip

Sutrip

sumatriptan

Manufacturer:

Vexxa Lifesciences

Distributor:

VE Pharma
Concise Prescribing Info
Contents
Sumatriptan succinate
Indications/Uses
Acute treatment of migraine attacks & cluster headache.
Dosage/Direction for Use
Adult ≥18 yr Acute treatment of migraine Administer orally as soon as possible after the onset of the headache phase. If no response is obtained w/ initial dose by any route, 2nd dose should not be given for the same attack. Further doses may be given at min 2-hr interval between doses & not >300 mg in the 24-hr period if symptoms recur. Lower dose of 25 mg may be used, although some patients require 50 or 100 mg, followed by a 2nd dose of up to 100 mg if the headache returns or the patient has a partial response provided that the total daily dose does not exceed the recommended max of 200 mg & at a min 2-hr interval between doses. Acute migraine Childn >12 yr Adult dose, 10-12 yr 50 mg, 6-10 yr 25 mg. May repeat at least 2 hr after if symptoms recur after an initial response. Hepatic impairment 50 mg.
Contraindications
Hypersensitivity. History of MI, peripheral vascular disease or symptoms or signs consistent w/ ischaemic heart disease, Prinzmetal's angina/coronary vasospasm, uncontrolled HTN, CVA or transient ischaemic attack. Severe hepatic impairment.
Special Precautions
Hypersensitivity to sumatriptan succinate & sulfonamides. Should not be given as IV because of the risk of producing coronary vasospasm. Should not be used for prophylaxis & should not be given to patients w/ basilar, hemiplegic or ophthalmoplegic migraine. Unrecognised CV disease should be excluded before use in postmenopausal women, men >40 yr & those w/ risk factors for ischaemic heart disease. Chest pain & tightness. Patients w/ history of epilepsy or other conditions predisposing to seizures. Hepatic or renal impairment. Drowsiness may occur & may affect ability to drive or operate machinery. Pregnancy & lactation.
Adverse Reactions
Dizziness, flushing, weakness, drowsiness, fatigue; nausea, vomiting; dyspnoea, sensory disturbance including paraesthesia & hypoaesthesia; pain or sensations of heaviness, heat/cold, pressure, or tightness; transient increases in BP; hypotension, bradycardia/tachycardia, palpitations, Raynaud's syndrome, ischaemic colitis; visual disturbances; medication-overuse headache. Occasionally, minor disturbances in liver function. Hypersensitivity reactions ranging from skin rashes to, more rarely, anaphylaxis; GI tract & resp system effects; ischaemic colitis, mesenteric ischaemia, oesophageal constriction or throat tightness. Pain or chest tightness or anginal pain; cerebral vasospasm.
Drug Interactions
Increased risk of vasospastic reactions w/ ergotamine or related compd including methysergide. Should not be used w/ MAOI & for 2 wk after stopping. St John's wort (Hypericum perforatum). Delayed gastric emptying & might affect the absorption of other drugs eg, paracetamol.
MIMS Class
Antimigraine Preparations
ATC Classification
N02CC01 - sumatriptan ; Belongs to the class of selective serotonin (5HT1) agonists preparations. Used to relieve migraine.
Presentation/Packing
Form
Sutrip FC tab 50 mg
Packing/Price
2's;5's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in